CD8A and hepatocellular carcinoma: Additionally, virus-like silica vaccines with spike-like structures co-deliver hepatocellular carcinoma neoantigens and TLR9 agonists, effectively enhancing CD8+ T cell responses against both primary and metastatic tumors [167].